Celcuity's triple cancer drug combo beats AstraZeneca in halting cancer progression, shows study
The drug, gedatolisib, in combination with Pfizer's Ibrance and AstraZeneca's endocrine therapy Faslodex, reduced the risk of disease progression or death by 76%, compared to Faslodex alone in previously treated HR /HER2- advanced breast cancer patients in a late-stage study.
HR /HER2- breast cancer accounts for about 70% of all breast cancers.
The combination treatment helped patients live for an average of 9.3 months without progression of the disease, compared to about two months with Faslodex.
Gedatolisib belongs to a class of drugs called PAM inhibitors, which include Novartis' Afinitor and AstraZeneca's Truqap.
The treatment was better tolerated in the late-stage trial than a previous early-stage study, with lower rates of high blood sugar and inflammation in the tissue lining the mouth, Celcuity said, without offering further details.
The study also showed that a double combination of gedatolisib and Ibrance reduced the risk of disease progression or death by 67%, compared to Faslodex. This combination increased survival without progression of the disease in patients by 7.4 months on average, compared to about two months with Faslodex.
Celcuity plans to report full results from this late-stage study and data from a separate trial in patients whose tumors had alterations in some genes later this year.
It expects to apply for U.S. marketing approval in the fourth quarter.
Shares of the Minnesota-based firm jumped nearly 114% to $29.4 before the bell.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
6 hours ago
- Time of India
AI-based screening detects five cancer cases in early stages
Low dose Chest CT scan for individuals with a significant history of exposure to tobacco between the ages of 55 to 74, has been validated as a screening tool for early diagnosis of lung cancer. Panaji: The AI-driven early detection of lung cancer screening has been carried out across all levels of the public health system for free in Goa since Feb 2024. Over 75,000 chest X-rays have been screened, detecting over 6,000 pulmonary nodules and flagging more than 500 people with high risk for lung cancer. It also detected five lung cancer cases that would have otherwise gone undetected. Under the public-private partnership, Goa, in partnership with AstraZeneca and is the first state in the country to deploy artificial intelligence for lung cancer screening in the public sector. This was presented at the 78th World Health Assembly in Geneva in May by the state nodal officer for non-communicable disease cell, Dr Kedar Raikar. The screening currently takes place at 17 public health centres and hospitals. It is integrated with the existing digital X-ray network and conducts chest X-rays, CT scans, and follow-ups. The programme has reduced the wait time for CT scan from 10 days to 2 days for high-risk patients. The system helps flag potential signs on routine X-rays even when patients come in for completely unrelated issues. Before the system was brought in, 100 to 200 lung cancer cases would be detected over a two-year period. A pink slip is given to high-risk patients to ensure they receive prioritised care quickly. Stay updated with the latest local news from your city on Times of India (TOI). Check upcoming bank holidays , public holidays , and current gold rates and silver prices in your area.
Economic Times
a day ago
- Economic Times
COVID wave is moving across USA: Health experts warn parents that children must do this
Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads FAQs Tired of too many ads? Remove Ads United States of America is witnessing a late-summer COVID wave, even as children are preparing to return to school. Fortunately, hospitalization rates remain low. The risk of severe illness and hospitalization among children younger than 1 who are infected with the coronavirus is comparable to that among adults 65 and older. That's why experts have said that a child's first exposure should be through a vaccine, rather than infection. However, this fall, it may not be possible for many parents to have a healthy child younger than age 5 immunized against COVID, as per a health experts noted that the coronavirus is still a threat, even for otherwise healthy children younger than 2. Among children ages 6 months to 2 years who were hospitalized with COVID from October 2022 to April 2024, more than half had no underlying medical conditions, according to data from the CDC, NYT News Service reported. Pfizer 's vaccine has long been available to these children under so-called emergency use authorization. But the Food and Drug Administration is considering discontinuing the authorization for that age group, according to an email sent by the Centers for Disease Control and Prevention to state and local health confirmed the possibility Monday evening and said that the company was "currently in discussions with the agency on potential paths forward." For children 5 to 11 years old, the Pfizer vaccine is expected to be approved and available, according to the CDC's email, which was reviewed by The New York July, the FDA granted full approval to Moderna's COVID vaccine for children -- but only for those who have health conditions that may put them at increased risk should they become infected. Novavax's COVID vaccine has never been available for children younger than upshot is that if the FDA does not renew Pfizer's authorization for children 6 months to 4 years, or fully approve the vaccine, healthy children in that age group will have no officially sanctioned options -- although doctors may still choose to provide the vaccine "off label."In May, Health Security Robert F. Kennedy Jr. announced that COVID vaccines would no longer be offered to healthy children or pregnant women. Kennedy has called the Pfizer and Moderna vaccines dangerous. In May 2021, in the thick of the pandemic, he filed a petition with the FDA demanding that the agency revoke authorization for the CDC, which typically makes such recommendations, later walked back the secretary's statement, saying that healthy children could get the shot if a doctor agreed that it was told the CDC it was ramping up supplies of its vaccine for the fall, according to the agency's email. But it is not approved for healthy children, and if the FDA rescinds authorization for children younger than 5, parents of healthy children will find themselves with no Nixon, a spokesperson for the Department of Health and Human Services, declined to comment on potential regulatory changes and said any reports before an official statement should be treated as "speculation."But public health experts noted that the coronavirus is still a threat, even for otherwise healthy children younger than 2. Among children ages 6 months to 2 years who were hospitalized with COVID from October 2022 to April 2024, more than half had no underlying medical conditions, according to data from the vaccines have also been shown to offer modest protection against long COVID in some children. The effects are already becoming apparent. Providers have stopped ordering last year's shot, as they often do at this time of the year. Normally by this point, there would be a clear plan for the 2025-26 season.A1. The full form of CDC is Centers for Disease Control and Prevention.A2. Full form of FDA is Food and Drug Administration.
Time of India
a day ago
- Time of India
COVID wave is moving across USA: Health experts warn parents that children must do this
Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads FAQs Tired of too many ads? Remove Ads United States of America is witnessing a late-summer COVID wave, even as children are preparing to return to school. Fortunately, hospitalization rates remain low. The risk of severe illness and hospitalization among children younger than 1 who are infected with the coronavirus is comparable to that among adults 65 and older. That's why experts have said that a child's first exposure should be through a vaccine, rather than infection. However, this fall, it may not be possible for many parents to have a healthy child younger than age 5 immunized against COVID, as per a health experts noted that the coronavirus is still a threat, even for otherwise healthy children younger than 2. Among children ages 6 months to 2 years who were hospitalized with COVID from October 2022 to April 2024, more than half had no underlying medical conditions, according to data from the CDC, NYT News Service reported. Pfizer 's vaccine has long been available to these children under so-called emergency use authorization. But the Food and Drug Administration is considering discontinuing the authorization for that age group, according to an email sent by the Centers for Disease Control and Prevention to state and local health confirmed the possibility Monday evening and said that the company was "currently in discussions with the agency on potential paths forward." For children 5 to 11 years old, the Pfizer vaccine is expected to be approved and available, according to the CDC's email, which was reviewed by The New York July, the FDA granted full approval to Moderna's COVID vaccine for children -- but only for those who have health conditions that may put them at increased risk should they become infected. Novavax's COVID vaccine has never been available for children younger than upshot is that if the FDA does not renew Pfizer's authorization for children 6 months to 4 years, or fully approve the vaccine, healthy children in that age group will have no officially sanctioned options -- although doctors may still choose to provide the vaccine "off label."In May, Health Security Robert F. Kennedy Jr. announced that COVID vaccines would no longer be offered to healthy children or pregnant women. Kennedy has called the Pfizer and Moderna vaccines dangerous. In May 2021, in the thick of the pandemic, he filed a petition with the FDA demanding that the agency revoke authorization for the CDC, which typically makes such recommendations, later walked back the secretary's statement, saying that healthy children could get the shot if a doctor agreed that it was told the CDC it was ramping up supplies of its vaccine for the fall, according to the agency's email. But it is not approved for healthy children, and if the FDA rescinds authorization for children younger than 5, parents of healthy children will find themselves with no Nixon, a spokesperson for the Department of Health and Human Services, declined to comment on potential regulatory changes and said any reports before an official statement should be treated as "speculation."But public health experts noted that the coronavirus is still a threat, even for otherwise healthy children younger than 2. Among children ages 6 months to 2 years who were hospitalized with COVID from October 2022 to April 2024, more than half had no underlying medical conditions, according to data from the vaccines have also been shown to offer modest protection against long COVID in some children. The effects are already becoming apparent. Providers have stopped ordering last year's shot, as they often do at this time of the year. Normally by this point, there would be a clear plan for the 2025-26 season.A1. The full form of CDC is Centers for Disease Control and Prevention.A2. Full form of FDA is Food and Drug Administration.
